Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.
Clinical trial NCT01336634 · COMPLETED
Trial details
- NCT number
- NCT01336634
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2011-08-05
- Primary completion
- 2015-10-01
- Enrollment
- 177
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.